Arcturus Therapeutics Holdings Inc.
$8.9
▲
2.29%
2026-04-21 05:22:01
arcturusrx.com
NGM: ARCT
Explore Arcturus Therapeutics Holdings Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$251.54 M
Current Price
$8.9
52W High / Low
$24.17 / $5.85
Stock P/E
—
Book Value
$7.53
Dividend Yield
—
ROCE
-32.48%
ROE
-28.92%
Face Value
—
EPS
$-2.4
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
106
Beta
2.44
Debt / Equity
11.68
Current Ratio
6.64
Quick Ratio
6.64
Forward P/E
-1.99
Price / Sales
2.9
Enterprise Value
$31.71 M
EV / EBITDA
-0.43
EV / Revenue
0.39
Rating
Buy
Target Price
$23.3
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Recursion Pharmaceuticals, Inc. | $3.69 | — | $1.95 B | — | -48.86% | -59.54% | $7.18 / $2.8 | $2.14 |
| 2. | Shattuck Labs, Inc. | $7.88 | — | $538.88 M | — | -61.34% | -60.25% | $7.68 / $0.71 | $1.3 |
| 3. | Pulmatrix, Inc. | $1.34 | — | $4.91 M | — | -135.67% | -80.93% | $9.37 / $1.16 | $1.04 |
| 4. | Impact BioMedical Inc. | $0.68 | — | $67.48 M | — | -26.29% | -1.04% | $1.95 / $0.36 | $0.12 |
| 5. | Rallybio Corporation | $8.29 | — | $43.48 M | — | -56.97% | -15.01% | $11.49 / $1.9 | $10.97 |
| 6. | PharmaCyte Biotech, Inc. | $0.76 | — | $7.82 M | — | -8.38% | -8.24% | $1.51 / $0.63 | $3.59 |
| 7. | Annexon, Inc. | $6.43 | — | $1.05 B | — | -92.11% | -81.9% | $7.18 / $1.4 | $1.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 3.08 M | 14.15 M | 24.51 M | 25.48 M | 21 M | — |
| Operating Profit | -31.31 M | -16.51 M | -11.62 M | -16.83 M | -33.39 M | — |
| Net Profit | -29.08 M | -13.45 M | -9.18 M | -14.08 M | -30 M | — |
| EPS in Rs | -1.02 | -0.47 | -0.32 | -0.5 | -1.06 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 67.22 M | 138.39 M | 157.75 M | 205.75 M |
| Operating Profit | -76.26 M | -95.67 M | -78.2 M | 12.18 M |
| Net Profit | -65.78 M | -80.94 M | -29.73 M | 9.35 M |
| EPS in Rs | -2.31 | -2.85 | -1.05 | 0.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 271.15 M | 344.07 M | 429.4 M | 450.39 M |
| Total Liabilities | 57.16 M | 103.09 M | 150.89 M | 180.07 M |
| Equity | 213.99 M | 240.98 M | 278.51 M | 270.31 M |
| Current Assets | 241.45 M | 305.98 M | 386.59 M | 403.33 M |
| Current Liabilities | 36.38 M | 65.49 M | 81.99 M | 126.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -74.27 M | -59.75 M | -18.1 M | 31.99 M |
| Investing CF | -0.23 M | -0.65 M | -2.9 M | -7.73 M |
| Financing CF | 13.38 M | 5.42 M | -24.09 M | -2.86 M |
| Free CF | -74.5 M | -60.4 M | -21 M | 24.27 M |
| Capex | -0.23 M | -0.65 M | -2.9 M | -7.73 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -12.27% | -23.33% | — | — |
| Earnings Growth % | -172.3% | -417.95% | — | — |
| Profit Margin % | -58.49% | -18.84% | 4.54% | — |
| Operating Margin % | -69.13% | -49.58% | 5.92% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -55.93% | -15.32% | 6.66% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.